Richard C. Harvey

14.6k total citations
48 papers, 2.3k citations indexed

About

Richard C. Harvey is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Molecular Biology. According to data from OpenAlex, Richard C. Harvey has authored 48 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Public Health, Environmental and Occupational Health, 27 papers in Hematology and 14 papers in Molecular Biology. Recurrent topics in Richard C. Harvey's work include Acute Lymphoblastic Leukemia research (38 papers), Chronic Myeloid Leukemia Treatments (21 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Richard C. Harvey is often cited by papers focused on Acute Lymphoblastic Leukemia research (38 papers), Chronic Myeloid Leukemia Treatments (21 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Richard C. Harvey collaborates with scholars based in United States, Canada and United Kingdom. Richard C. Harvey's co-authors include Stephen P. Hunger, Cheryl L. Willman, I‐Ming Chen, Sarah K. Tasian, Charles G. Mullighan, John B. Faust, O.O. Melnyk, T C Meeker, D A Withers and Mignon L. Loh and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Richard C. Harvey

48 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard C. Harvey United States	20	1.3k	1.1k	695	628	590	48	2.3k
Susanne Viehmann Germany	21	1.3k 1.0×	1.6k 1.5×	995 1.4×	325 0.5×	313 0.5×	33	2.6k
Letha A. Phillips United States	8	1.3k 1.0×	1.3k 1.2×	1.0k 1.5×	466 0.7×	533 0.9×	15	2.5k
C Charrin France	24	1.1k 0.8×	1.3k 1.2×	433 0.6×	410 0.7×	265 0.4×	60	1.9k
SC Raimondi United States	21	1.4k 1.1×	1.4k 1.3×	751 1.1×	323 0.5×	232 0.4×	46	2.2k
FG Behm United States	36	2.2k 1.7×	2.1k 1.9×	922 1.3×	538 0.9×	544 0.9×	65	3.4k
Jan Trka Czechia	34	2.0k 1.5×	2.1k 1.9×	1.5k 2.2×	452 0.7×	654 1.1×	149	3.7k
Mårina Lafage‐Pochitaloff France	29	1.1k 0.8×	2.2k 2.0×	1.4k 2.1×	723 1.2×	353 0.6×	76	3.7k
Paula Gameiro Portugal	14	798 0.6×	1.1k 1.0×	726 1.0×	229 0.4×	143 0.2×	29	1.8k
Li Chong Chan Hong Kong	20	366 0.3×	735 0.7×	1.1k 1.6×	335 0.5×	377 0.6×	39	2.2k
Helena Kempski United Kingdom	22	622 0.5×	820 0.7×	747 1.1×	389 0.6×	206 0.3×	42	2.0k

Countries citing papers authored by Richard C. Harvey

Since Specialization

Citations

This map shows the geographic impact of Richard C. Harvey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard C. Harvey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard C. Harvey more than expected).

Fields of papers citing papers by Richard C. Harvey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard C. Harvey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard C. Harvey. The network helps show where Richard C. Harvey may publish in the future.

Co-authorship network of co-authors of Richard C. Harvey

This figure shows the co-authorship network connecting the top 25 collaborators of Richard C. Harvey. A scholar is included among the top collaborators of Richard C. Harvey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard C. Harvey. Richard C. Harvey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Salzer, Wanda L., Michael J. Burke, Meenakshi Devidas, et al.. (2023). Feasibility and Outcome of Post-Induction Therapy Incorporating Dasatinib for Patients with Newly Diagnosed ABL-Class Fusion B-Lymphoblastic Leukemia (ABL-class Fusion B-ALL): Children's Oncology Group AALL1131. Blood. 142(Supplement 1). 961–961. 3 indexed citations

Ding, Yangyang, Gerald Wertheim, Fumin Lin, et al.. (2018). Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure. Haematologica. 103(9). e427–e431. 46 indexed citations

Schwab, Claire, Amir Enshaei, Kathryn G. Roberts, et al.. (2016). The Frequency and Outcome of Ph-like ALL Associated Abnormalities in Childhood Acute Lymphoblastic Leukaemia Treated on MRC UKALL2003. Blood. 128(22). 2914–2914. 5 indexed citations

Tasian, Sarah K., David T. Teachey, Yong Li, et al.. (2016). Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 129(2). 177–187. 110 indexed citations

Tasian, Sarah K., Yong Li, Feng Shen, et al.. (2015). Potent Efficacy of Combined PI3K/mTOR and JAK or SRC/ABL Inhibition in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia. Blood. 126(23). 798–798. 2 indexed citations

Raetz, Elizabeth A., Mignon L. Loh, Meenakshi Devidas, et al.. (2015). Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). Blood. 126(23). 807–807. 4 indexed citations

Tenhagen, Milou, Jeroen Bakker, Richard C. Harvey, et al.. (2015). RasGRP1 overexpression in T-ALL increases basal nucleotide exchange on Ras rendering the Ras/PI3K/Akt pathway responsive to protumorigenic cytokines. Oncogene. 35(28). 3658–3668. 35 indexed citations

Roberts, Kathryn G., Yung‐Li Yang, Debbie Payne-Turner, et al.. (2015). Abstract PR02: Investigating the use of tyrosine kinase inhibitors in Ph-like ALL.. Clinical Cancer Research. 21(17_Supplement). PR02–PR02. 1 indexed citations

Suryani, Santi, Richard C. Harvey, Hernán Carol, et al.. (2014). Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia. Molecular Cancer Therapeutics. 14(2). 364–374. 43 indexed citations

10.

Yang, Ming, Christopher C. Govern, Arup K. Chakraborty, et al.. (2012). Dysregulated RasGRP1 Responds to Cytokine Receptor Input in T Cell Leukemogenesis. DSpace@MIT (Massachusetts Institute of Technology). 39 indexed citations

11.

Meng, Xiangbing, Ksenia Matlawska‐Wasowska, François Girodon, et al.. (2011). GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia. Leukemia. 25(7). 1135–1146. 32 indexed citations

12.

Harvey, Richard C., Charles G. Mullighan, I‐Ming Chen, et al.. (2010). Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 115(26). 5312–5321. 395 indexed citations

13.

Zhang, Jinghui, Charles G. Mullighan, Richard C. Harvey, et al.. (2010). Lack of Somatic Sequence Mutations In Protein Tyrosine Kinase Genes Other Than the JAK Kinase Family In High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project. Blood. 116(21). 2752–2752. 4 indexed citations

14.

Su, Nan, Yuan‐Xiang Pan, Mi Zhou, et al.. (2007). Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. Pediatric Blood & Cancer. 50(2). 274–279. 73 indexed citations

15.

Gastier‐Foster, Julie M., Andrew J. Carroll, Richard C. Harvey, et al.. (2007). Two Distinct Subsets of dic(9;12)(p12;p11.2) among Children with B-Cell Precursor Acute Lymphoblastic Leukemia (ALL): PAX5-ETV6 and ETV6-RUNX1 Rearrangements: A Report from the Children’s Oncology Group.. Blood. 110(11). 1439–1439. 3 indexed citations

16.

Stock, Wendy, Richard C. Harvey, Barry Kurt Moser, et al.. (2006). Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710.. Blood. 108(11). 494–494. 2 indexed citations

17.

Harvey, Richard C., et al.. (1992). An attempt to eradicate Herpesvirus simiae from a rhesus monkey breeding colony.. PubMed. 42(5). 458–62. 8 indexed citations

18.

Withers, D A, Richard C. Harvey, John B. Faust, et al.. (1991). Characterization of a candidate bcl-1 gene.. Molecular and Cellular Biology. 11(10). 4846–4853. 291 indexed citations

19.

Withers, Donald A., Richard C. Harvey, John B. Faust, et al.. (1991). Characterization of a Candidate bcl-1 Gene. Molecular and Cellular Biology. 11(10). 4846–4853. 71 indexed citations

20.

Kacian, Daniel & Richard C. Harvey. (1985). Purification of plasminogen activator from rous sarcoma virus-infected chick embryo fibroblast culture medium. Archives of Biochemistry and Biophysics. 236(1). 354–369. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact